6,8a-deoxy derivatives of avermectins produced by a mutant strain of Streptomyces avermitilis K20571} derived by mutation from strain K2038 producing avermectins B l a and B2a selectively2). The parent strain K2038carries two types of mutations, C-5 0-methylation (aveD) and the selective incorporation of branched-chain fatty acid into the avermectin molecule (X). The mutant strain K2057 has an additional mutation (aveE) affecting furan ring formation at C-6 and C-8a positions besides both mutations aveDand X. Wecould not detect methylated 6,8a-seco-6,8a-deoxy derivatives of avermectins from mutant K2057 because the mutant lacks functions required for methylation at position C-5. Although some of methylated 6,8a-seco-6,8a-deoxy derivatives of avermectins have been reported by Chen and Inamine3), 4'-deoleandrosyl-6,8a-seco-6,8a-deoxyavermectin Ala has not been described. Since the mutant K2057 produced a relatively large amount of 4'-deoleandrosyl-6,8a-seco-6,8a-deoxyavermectin B la, if C-5 (9-methylation {aveD)
could be restored, the revertant would likely produce the new compound, 4'-deoleandrosyl-6,8a-seco-6,8a-deoxyavermectin A l a.
In this communication, we describe the production of the new 6,8a-seco-6,8a-deoxy derivative of avermectins by introducing the gene for the C-5 O-methylation step from the wild type strain of S. avermitilis into mutant K2057.
Transformants were obtained from the mutant strain K2057 (aveD aveE X) by introduction of the recombinant plasmid pKU109:: aveD139, which consisted of Streptomyces vector pKU1094) and the 3.4 kbp BamHI fragment encoding the C-5 O-methylation step of avermectin biosynthesis from wild type strain K139. Conditions for the production were as described previously5'63 except that 5 fig of thiostrepton per milliliter was added in the medium to prevent plasmid loss. Mutant K2057 produces seven compounds lacking a furan ring at C-6 and C-8a positions1*. Transformants of K2057carrying a gene for C-5 O-methylation step produced at least nine avermectin-related compounds.
Seven of them were identical to the compoundsproduced by K2057. It was anticipated that the other two components would be methylated derivatives. Mycelia were harvested from 600-ml culture by centrifugation and the avermectin derivatives were extracted with acetone. The acetone extract was evaporated and the concentrate was extracted with methylene chloride to provide about 730 mg of oily material, which was applied to preparative silica gel thin layer chromatography and developed with «-hexane-2-propanol (85: 15). The fractions corresponding to new components were collected and eluted with methylene chloride -methanol (3: 1). The eluate was concentrated to dryness and Cultivation and preparation of the mycelial extract were described previously1}. Conditions for HPLC were as described in references 1 and 4. Identified peaks were as follows; I: 6,8a-seco-6,8a-deoxyavermectin B2a, II: 6,8a-seco-6,8a-deoxyavermectin Bla, III: 4'-deoleandrosyl-6,8a-seco-6,8a-deoxyavermectin Bla, IV: 4'-deoleandrosyl-6,8a-seco-6,8a-deoxy-5-oxoavermectin B2a, V: 6,8a-seco-6,8a-deoxy-2,5-didehydroavermectin B2a, VI: 4'-deoleandrosyl-6,8a-seco-6,8a-deoxy-5-oxoavermectin B l a and VII: 6,8a-seco-6,8a-deoxy-5-oxoavermectin Bla aglycone. Spectra were recorded in CDC13solution; chemical shifts are given in ppmand coupling constants are given in Hz. 14.0, 2.0 Hz) in avermectin Ala aglycone were not found in compound1 and two different signals, a methylene proton ofH-6 (3.45ppm, 2H, m) and a methyl proton of H-8a (1.72ppm, 3H, s) were observed. These results indicate that compound 1 is identical to 6,8a-seco-6,8a-deoxyavermectin Ala aglycone3'7) which is considered to be derived from 6,8a-seco-6,8a-deoxyavermectin Bla aglycone by methylation at 5-OHwith the gene product of the aveD gene. Interestingly, this aglycone, 6,8a-seco-6,8a-deoxyavermectin Bla aglycone, was not detected amongthe fermentation products of the parent K2057. The XH NMRspectrum of compound 2 was extremely similar to that of 4'-deoleandrosyl-6,8a-seco-6,8a-deoxyavermectin Bla although a new proton signal was observed with compound 2 ( Table 2 ). The signal was identified to the methoxy proton (3.37ppm, 3H, s) at C-5 position. The mass spectral pattern of compound 2 indicates the addition of one carbon and two hydrogen atoms and it was concluded that compound2 is a new avermectin derivative, 4'-deoleandrosyl-6,8a-seco-6,8a-deoxyavermectin Ala (Fig. 2) .
The recombinant strain, K2057 carrying pKU109 :: aveD139, and the mutant isolated by Chen and Inamine31 are isogenic except for the X phenotype, but the recombinant strain produced a new compound, 4'-deoleandrosyl-6,8a-seco-6,8a-deoxyavermectin Ala. The recombinant strain contains about 50 copies of the methylation gene {aveD) per chromosome (data not shown) although chromosomal aveD gene is not functional in the recombinant strain because the parent strain K2057was derived from aveD mutant. The aveD gene in the mutant isolated by Chen and Inamine3) would be a single copy in the chromosome. Since the methylation activities of the recombinant strain was much higher than that of wild type strain K139 (data not shown), the recombinant strain could accumulate a new methylated compound. The aveE mutant might also be expected to produce this new methylated compound if a high copy number plasmid carrying the C-5 Omethylation gene, aveD, was introduced. 
